Weight Loss Drugs and the Loss of Skeletal Muscle Mass A commentary in The Lancet emphasizes the importance of skeletal muscle mass in medically induced weight loss, especially with the use of GLP-1 receptor agonists. While these drugs are effective for obesity treatment, there… https://t.co/8AOgDUajw6 https://t.co/0vntwZSpLy

Survey of UK Rheumatology pts (n 876 found 55% take daily supplements costing £10 to £200 per month (most common: vit D, C, B complex, MVI Omega 3/6). 82% take Prescription, OTC, or non-prescription pain meds, 13% sleep aids. Half of NSAID pts also take OTC supplements… https://t.co/VpMG9SiE1E https://t.co/SJYUfogeVJ

Nationwide Readmissions Database (NRD) study of 133,187 #RA pts found that 48% were "frail". Hospital readmissions were significantly higher in the RA frail pts (57% vs 31%), & hospitalized, frail patients also had significantly higher mortality (3.36% vs 0.39%) & longer LOS… https://t.co/6lF4wrC87B https://t.co/mWJGIPbEjc

A Keto Diet for Autoimmune Disorders? Scientists have long suspected the keto diet might be able to calm an overactive immune system and help some people with diseases like multiple sclerosis. https://t.co/7mX6Ue4FdX https://t.co/qtOwdKfqu4

ACIP now recommendsa pneumococcal conjugate vaccine (PCV) for all PCV-naive adults >50 yrs. Single dose of PCV (PCV15, PCV20, or PCV21) in adults >50 yrs. Pt 19-64 yrs w/ underlying conditions (prev. recommended) could recv the newly approved PCV21. https://t.co/es4KUuiYqy https://t.co/rVcIgZOLjx

In an RCT of colchicine vs PBO in #gout for 6 months shows that colchicine prophylaxis when initiating ULT did not increase the odds of achieving gout remission. https://t.co/kgNzw0UUIq https://t.co/ZdBT0Fp9Gx

Cross-sectional study of 176 CASPAR+ PsA patients correlated Dz activity (cDAPSA) w/ SAA, IL-8, IP10 (IFNg/CXCL10), M-CSF, SCGF-β, SDF-1α) (AUC 0.802- 0.835). The panel was significantly better than CRP (AUC = 0.727, p = 0.022). https://t.co/AZq81S6NH0 https://t.co/5eI241gLVj

Metanalysis of 26 RCTs suggests JAK inhibitors have a low, but signif. increased risk of infections (vs placebo) (RR 1.39; 1.096-1.76). No risk of tuberculosis or hepatitis, but an incr. risk of H. zoster was seen (RR 1.71; 0.84-3.51) https://t.co/kXOcldz46l https://t.co/Y5OWk4W1NZ

Iberdomide Efficacy in Cutaneous Lupus berdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).… https://t.co/2LtBDOIBrN https://t.co/giVDgZBiyk

Over a 16 yr span & 988 LBP referrals - 366 (37%) Dx w/ axSpA, w/ increase in # women w/ axSpA. Mean time to Dx decreased 9.8 yrs (2008) to 1 yr (2023). Greatest delay was LBP onset to GP eval. (3.2 yrs). Referral time improved by organizational change https://t.co/bEmaspJWG4 https://t.co/Jyo1neMGib

Serial MRI study of SI & lumbar (LS) joints in 24 early axSpA (Sxs < 5.5yrs) over 3 yrs, showed: - SIJ developed bone marrow edema, sclerosis & erosion. - LS: fat lesions decreased & erosions increased. - Facet joint inflammation (in t0) significantly influenced yr 3. LS bony… https://t.co/czBPVXYHYa https://t.co/6ByhsXONtf

FDA's perspective on the use of artificial intelligence in drug development. - FDA is committed to a risk-based regulatory framework that promotes innovation & protects Pt safety - Est. CDER AI Council to coordinate, develop, & support internal & external AI-related activities… https://t.co/BLCYmBBJMY https://t.co/fMie3oOfmn